7 assets in Myeloproliferative Neoplasm, Unclassifiable

Therapeutic assets addressing Myeloproliferative Neoplasm, Unclassifiable, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Decitabine Myeloproliferative Neoplasm, Unclassifiable	University of Washington	P2	CCC (53)
Fedratinib Myeloproliferative Neoplasm, Unclassifiable	University of Washington	P2	CCC (53)
Ruxolitinib Myeloproliferative Neoplasm, Unclassifiable	University of Washington	P2	CCC (53)
Azacitidine Myeloproliferative Neoplasm, Unclassifiable	M.D. Anderson Cancer Center	P1/2	CCC (48)
Pevonedistat Myeloproliferative Neoplasm, Unclassifiable	M.D. Anderson Cancer Center	P1/2	CCC (48)
Venetoclax Myeloproliferative Neoplasm, Unclassifiable	M.D. Anderson Cancer Center	P1/2	CCC (48)
Pacritinib Myeloproliferative Neoplasm, Unclassifiable	University of Washington	P2	CC (46)